Connect with us

Hi, what are you looking for?

Science & Technology

Ground-breaking Wafer-like Migraine Treatment to be Available on NHS

An image of multiple blister packs filled with different coloured and shaped pills.
Photo by Volodymyr Hryshchenko on Unsplash

Science and Research Correspondent Jana Bazeed discusses a new treatment for migraine prevention that will soon be available on the NHS.

For the first time, NICE has recommended an oral treatment for migraine prevention.

As of 5 July, 2023, the UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of Pfizer’s Rimegepant (sold under the brand name Vydura) as a treatment for episodic migraines in adults.  

This recommendation gives 145,000 people a further treatment option on the NHS to help prevent episodic migraines. According to NICE, it is estimated that around 5.6 million people experience these migraines in England, with approximately 190,000 migraine attacks happening daily.

Rimegepant will only be available to adults who have previously tried at least three other preventative drugs and still have between 4-15 migraine attacks per month.

The drug works by inhibiting the binding of calcitonin gene-related peptide (CGRP), a protein found near the brain, preventing its interaction with its intended receptors. CGRP is responsible for inducing significant inflammation and the excruciating pain linked to migraine attacks.

Current treatment options include the use of drugs used for other conditions, such as antidepressants and epilepsy medications, which can have significant side-effects and can be ineffective for some patients. After these drugs have been tried, NICE recommends the use of erenumab, fremanezumab or galcanezumab. King’s research was central to the recommendation of these drugs, which are all administered via injections.

The medicated dissolving wafers are welcomed as a more convenient and less invasive treatment option.  Professor Peter Goadsby, from King’s College London, said: “Today’s decision offers an important advance in treatment options for those who do not respond or cannot tolerate current treatments.”

Professor Goadsby has been working in this area for decades and has led groundbreaking research at King’s identifying the role of the CGRP and testing treatments tailored specifically for migraine attacks.

The treatment should be available on NHS in England within the next three months.


KCLWRFC celebrate LUSL success


The King’s College London Students’ Union (KCLSU) told Roar in March that “additional funds” were being invested in facilitating teams taking part in “high...


Staff writer Deborah Solomon explains the roots of the current conflict in the Democratic Republic of the Congo and argues that the colonial past...

Chinese flag Chinese flag


The National, a pro-independence newspaper based in Glasgow, misidentified an individual who was today charged with spying on behalf of the Chinese government as...


Staff writer Claire Ducharme takes a look into the developments of slow fashion Australia and provides some tips on how to shop more sustainably....

A view of Downtown Yangon; picture taken by the author. A view of Downtown Yangon; picture taken by the author.


Staff Writer Eugenio Corrias provides personal insight into Operation 1027 in Myanmar and the future of democracy in the nation. In 2022, The Economist’s...


Roar News collected five of the eight awards it was nominated for at this year’s Student Publication Association National Convention (SPANC). The publication came...


Staff writer Meher Kazmi examines the UK’s deteriorating public services and argues for a drastic strategy to save them from disrepair. In the few...


Staff writer Hannah Durkin Review’s The Kings Shakespeare Company’s production of A Midsummer Night’s Dream. Feeling mildly frazzled and irked by the swarm of...


KCL Jazz Society will host a free end-of-semester concert – ‘Swinging and Singing’ – on Wednesday 10 April, from 16:00 until 18:00 in the Greenwood Theatre....